三阴性乳腺癌免疫治疗的临床应用进展  

Advances in clinical application of immunotherapy for triple-negative breast cancer

作　　者：张亮[1,2] 杨彦强 吴梓芳 刘九洋[1] ZHANG Liang;YANG Yanqiang;WU Zifang;LIU Jiuyang(Department of Thyroid and Breast Surgery,Zhongnan Hospital of Wuhan University,Wuhan 430071,Hubei Province,China;Department of Oncology,Urumqi Friendship Hospital,Urumqi 830049,Xinjiang Uygur Autonomous Region,China;Department of General Surgery,People's Hospital of Gannan Tibetan Autonomous Prefecture of Gansu Province,Gannan 747000,Gansu Province,China;Department of Ultrasound Imaging,Wuhan University Hospital,Wuhan 430071,Hubei Province,China)

机构地区：[1]武汉大学中南医院甲状腺乳腺外科,湖北武汉430071 [2]乌鲁木齐市友谊医院肿瘤科,新疆乌鲁木齐830049 [3]甘肃省甘南藏族自治州人民医院普外一科,甘肃甘南747000 [4]武汉大学医院超声影像科,湖北武汉430071

出　　处：《世界临床药物》2024年第8期803-808,813,共7页World Clinical Drug

摘　　要：三阴性乳腺癌(triple-negative breast cancer,TNBC)是一种雌激素受体、孕激素受体和人类表皮生长因子受体2阴性的乳腺癌亚型,其侵袭性及疾病进展速度明显高于其他亚型。目前其主要治疗为手术联合化疗,但晚期TNBC患者的治疗效果不佳。随着对TNBC免疫微环境深入研究,免疫疗法已显示出潜在的治疗价值。TNBC免疫治疗主要包括免疫检查点阻断剂、细胞治疗、肿瘤疫苗以及调整肿瘤微环境。该文对免疫疗法的现状和进展作回顾及总结,有助于TNBC免疫治疗的新认识。Triple-negative breast cancer(TNBC)is a subtype of breast cancer that is negative for estrogen receptors,progesterone receptors,and human epidermal growth factor receptor 2,and is significantly more aggressive and progressive than other subtypes.At present,the main treatment is surgery combined chemotherapy,but treatment efffcacy of the advanced TNBC patients is poor.With the in-depth study of TNBC immune microenvironment,immunotherapy has shown potential therapeutic value.The immunotherapy of TNBC mainly includes immune checkpoint blockers,cell therapy,tumor vaccines and adjustment of tumor microenvironment.This article reviewed and summarized the current status and progress of immunotherapy,which contributed to the new understanding of TNBC immunotherapy.

关 键 词：三阴性乳腺癌 免疫治疗 肿瘤微环境 

分 类 号：R737.9[医药卫生—肿瘤]